Clinical Trial

Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Study acronym: TERTIO
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The TERTIO trial will propose to determine the clinical interest and immunological efficacy of a treatment combining the CD4 helper T-inducer cancer anti-telomerase vaccine (UCPVax) with anti-PD-L1 therapy (atezolizumab) and bevacizumab in unresectable HCC by evaluation of the objective response rate at 6 months (randomized phase II, 10 centers, 105 patients)
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-09-01; most recent amendment 2026-03-13.
Status change: Not Yet Recruiting → Recruiting 2022-10-10
Trial Details
NCT Number NCT05528952
Lead Sponsor Centre Hospitalier Universitaire de Besancon
Collaborators: GERCOR - Multidisciplinary Oncology Cooperative Group, PRODIGE
Conditions Hepatocellular Carcinoma
Enrollment 105 participants
Start Date 2022-09-27
Primary Completion 2028-03-27 (estimated)
Study Completion 2030-02-27 (estimated)
Updated on ClinicalTrials.gov 2026-03-16